Alpha 2.0
Login Register
» Authors » Mathieu Fiore

Mathieu Fiore

Explore the profile of Mathieu Fiore including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 45
Citations 298
Followers 0
Related Specialties
Hematology
Cardiology & Vascular Diseases
Genetics
Top 10 Co-Authors
Xavier Pillois
Alan T Nurden
Paquita Nurden
Marie-Christine Alessi
Chloe James
Yoann Huguenin
Marie Tuffigo
Roland Heilig
Jean-Claude Bordet
Cecile Lavenu-Bombled
Published In
Platelets
J Thromb Haemost
Res Pract Thromb Haemost
Semin Thromb Hemost
Br J Haematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Fiore M, Guy A, James C
J Vis Exp . 2024 Dec; (213). PMID: 39671342
Activated platelets promote coagulation primarily by exposing the procoagulant phospholipid phosphatidylserine (PS) on their outer membrane surfaces and releasing PS-expressing microvesicles that retain the original membrane architecture and cytoplasmic components...
2.
Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review
Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M, et al.
Haemophilia . 2024 Nov; 31(1):7-15. PMID: 39604156
Background: Platelet transfusion is considered the standard treatment for preventing or controlling severe haemorrhage in Glanzmann thrombasthenia (GT). However, platelet transfusion can have detrimental effects, including the production of anti-GPIIb/IIIa...
3.
Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study
Dubut J, Goin V, Derray C, Huguenin Y, Fiore M
J Thromb Haemost . 2024 Jun; 22(9):2589-2600. PMID: 38880178
Background: Glanzmann thrombasthenia (GT) is caused by an inherited defect of platelet αβ integrin. Concizumab, a monoclonal antibody specific for tissue factor pathway inhibitor, abolishes its anticoagulant effect. Objectives: To...
4.
Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC
Gresele P, Falcinelli E, Bury L, Alessi M, Guglielmini G, Falaise C, et al.
Res Pract Thromb Haemost . 2024 Jan; 8(1):102305. PMID: 38292347
Background: In hemophilia and von Willebrand disease, the degree of alteration of laboratory assays correlates with bleeding manifestations. Few studies have assessed the predictive value for bleeding of laboratory assays...
5.
characterization of rare anti-αβ isoantibodies produced by patients with Glanzmann thrombasthenia that severely block fibrinogen binding and generate procoagulant platelets via complement activation
Lee C, Huguenin Y, Pillois X, Moulieras M, Marcy E, Whittaker S, et al.
Res Pract Thromb Haemost . 2024 Jan; 8(1):102253. PMID: 38268518
Background: Glanzmann thrombasthenia (GT) is a rare bleeding disorder caused by inherited defects of the platelet αβ integrin. Platelet transfusions can be followed by an immune response that can block...
6.
Emergency management of patients with Glanzmann thrombasthenia: consensus recommendations from the French reference center for inherited platelet disorders
Fiore M, Giraudet J, Alessi M, Falaise C, Desprez D, dOiron R, et al.
Orphanet J Rare Dis . 2023 Jun; 18(1):171. PMID: 37386449
Glanzmann thrombasthenia (GT) is a genetic bleeding disorder characterised by severely reduced/absent platelet aggregation in response to multiple physiological agonists. The severity of bleeding in GT varies markedly, as does...
7.
Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
Alessi M, Coxon C, Ibrahim-Kosta M, Bacci M, Voisin S, Rivera J, et al.
J Thromb Haemost . 2023 Jun; 21(9):2596-2610. PMID: 37331519
Background: Light transmission aggregation (LTA) is used widely by the clinical and research communities. Although it is a gold standard, there is a lack of interlaboratory harmonization. Objectives: The primary...
8.
Combined Platelet and Red Blood Cell Recovery during On-pump Cardiac Surgery Using same™ by i-SEP Autotransfusion Device: A First-in-human Noncomparative Study (i-TRANSEP Study)
Mansour A, Beurton A, Godier A, Rozec B, Zlotnik D, Nedelec F, et al.
Anesthesiology . 2023 Jun; 139(3):287-297. PMID: 37294939
Background: Centrifugation-based autotransfusion devices only salvage red blood cells while platelets are removed. The same™ device (Smart Autotransfusion for ME; i-SEP, France) is an innovative filtration-based autotransfusion device able to...
9.
Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study
Hugon-Rodin J, Carriere C, Claeyssens S, Trillot N, Drillaud N, Biron-Andreani C, et al.
J Thromb Haemost . 2023 May; 21(8):2126-2136. PMID: 37172732
Background: Women with hereditary fibrinogen disorders (HFDs) seem to be at an increased risk of adverse obstetrical outcomes, but epidemiologic data are limited. Objectives: We aimed to determine the prevalence...
10.
Platelet function studies in myeloproliferative neoplasms patients with or mutation
Guy A, Helzy K, Mansier O, Bordet J, Riviere E, Fiore M, et al.
Res Pract Thromb Haemost . 2023 Mar; 7(2):100060. PMID: 36908768
Background: and mutations are the most frequent molecular causes of -negative myeloproliferative neoplasms (MPN). Patients with mutations are at lower risk of thrombosis than patients with . We hypothesized that...